Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Sustainable complete remission in recurrence yolk sac tumor patient treated with tandem high-dose chemotherapy and autologous stem cell
N. A. Abdullah1, P. N. Wang2, K. G. Huang3,*, A. S. Adlan4, J. Casanova5
1 Department of Obstetrics & Gynecology, Sultanah Bahiyah Hospital, Kedah (Malaysia)
2 Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Kwei-Shan, Tao-Yuan (Taiwan)
3 Department of Obstetrics and Gynecology Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Kwei-Shan, Tao-Yuan (Taiwan)
4 Department of Obstetrics and Gynecology. University Malaya Medical Center, Faculty of Medicine, University of Malaya, Kuala Lumpur (Malaysia)
5 Department of Obstetrics & Gynecology, Centro Hospitalar do Porto, Porto (Portugal)
Eur. J. Gynaecol. Oncol. 2013, 34(2), 183–185;
Published: 10 April 2013
A 21-year-old lady diagnosed with Stage 3 ovarian yolk sac tumor (YST) underwent primary cytoreductive fertility sparing surgery, followed by conventional courses of platinum-based chemotherapy and etoposide. Recurrence at cul-da-sac was noted after a short period of remission and secondary debulking performed followed by four cycles of conventional chemotherapy. The patient’sdisease progressed despite courses of treatments. A joint team management including a hematologist was commenced following the failure of conventional chemotherapies. Two cycles of high-dose chemotherapy (HDCT) with ifosfamide/cisplatin/etoposide (ICE) regimen, followed by autologous stem cell transplantation (ASCT) were given. With this salvage treatment, she remained in complete remission and disease-free for more than 30 months, while maintaining her reproductive function. These approaches appear to be effective as a salvage treatment in selected cases of patients with ovarian germ cell tumor, especially those who failed primary conventional chemotherapy.
Germ cell tumor
Autologous stem cell